文献速递前列腺癌

favorable-risk Gleason分级分组2前列腺癌主动监测进展的性质

The Nature of Progression on Active Surveillance for Favorable-risk Gleason Grade Group 2 Prostate Cancer.
PubMed 文献 · Eur Urol Oncol · 2026-10-22

该研究基于加州大学旧金山分校2000-2025年329例确诊为 favorable-risk GG2前列腺癌并接受主动监测的男性队列,描述其进展特征。中位随访至10年时,疾病进展率79%、升级率58%、接受主动治疗率65%,转移率3.3%,无前列腺癌特异性死亡事件。PSA密度和基线mpMRI阳性与疾病进展及主动治疗相关。

要点

  • 确诊favorable-risk GG2前列腺癌主动监测10年疾病进展率达79%,需主动治疗率65%。
  • 10年转移率3.3%,无前列腺癌特异性死亡事件,但置信区间宽需外部验证。
  • PSA密度和基线mpMRI阳性(PI-RADS 4-5)与疾病进展及主动治疗相关。

核心结论

  • 确诊favorable-risk GG2前列腺癌男性主动监测10年疾病进展需治疗率中等,转移和前列腺癌特异性死亡率低但置信区间宽需外部验证。
  • PSA密度和基线mpMRI阳性与疾病进展相关,可帮助调整主动监测强度。

研究设计与样本

  • 单中心回顾性队列研究,纳入加州大学旧金山分校2000-2025年329例确诊为cT1-2N0/xM0/x、PSA<20 ng/ml、穿刺阳性针数≤50%、GG2且无expansile cribriform或导管内癌、主动监测期间接受≥2次穿刺的男性。
  • 采用Cox比例风险回归模型识别主动监测结局的危险因素。

主要发现

  • 5年和10年随访时,升级率分别为31%和58%,体积增至>50%率分别为22%和31%。
  • 5年和10年随访时,EC/IDC发生率分别为10%和41%,疾病进展率分别为44%和79%,主动治疗率分别为46%和65%。
  • 5年和10年转移率分别为0.80%和3.3%,根治性前列腺切除术后5年复发率为32%,10年内无前列腺癌特异性死亡事件。
  • PSA密度和基线mpMRI阳性(PI-RADS 4-5)与疾病进展和主动治疗相关。

临床怎么用

  • 对确诊favorable-risk GG2前列腺癌患者,主动监测是可选的管理策略,但需告知10年疾病进展和主动治疗的中等风险。
  • 可利用PSA密度和基线mpMRI结果(PI-RADS 4-5)辅助识别疾病进展风险较高的患者,从而调整主动监测强度。

局限性

  • 单中心队列,人群以白人为主。
  • mpMRI和基因组检测不完整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Active surveillance (AS) is a recommended option for favorable-risk Gleason grade group 2 (GG2) prostate cancer (PCa), but uptake varies. OBJECTIVE: To describe the nature of progression of confirmed GG2 disease in a well-annotated AS cohort. DESIGN, SETTING, AND PARTICIPANTS: Participants at the University of California, San Francisco, were diagnosed with cT1-2N0/xM0/x, prostate-specific antigen (PSA) <20 ng/ml, core positivity ≤50%, and GG2 PCa without expansile cribriform or intraductal carcinoma (EC/IDC) at diagnosis, with two or more biopsies on AS from 2000 to 2025. INTERVENTION: Active surveillance. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Outcomes were upgrade (GG3 or higher), volume increase to >50%, EC/IDC, disease progression (upgrade, volume increase, or EC/IDC), active treatment, recurrence (biochemical recurrence or salvage treatment) after radical prostatectomy (RP), metastasis, and PCa-specific mortality (PCSM). Cox proportional hazards regression models were used to identify risk factors for AS outcomes. RESULTS AND LIMITATIONS: A total of 329 men were included. At 5 and 10 yr of follow-up, respectively, the upgrade rate was 31% and 58%, volume increase rate was 22% and 31%, EC/IDC development rate was 10% and 41%, disease progression rate was 44% and 79%, active treatment rate was 46% and 65%, and metastasis rate was 0.80% and 3.3%. The 5-yr post-RP recurrence rate was 32%. No PCSM events were recorded within 10 yr. PSA density (PSAD) and positive baseline multiparametric magnetic resonance imaging (mpMRI; Prostate Imaging Reporting and Data System 4-5) were associated with disease progression and active treatment. Limitations include the single-institution cohort, a largely Caucasian population, and incomplete mpMRI and genomic testing. CONCLUSIONS: Men with confirmed favorable-risk GG2 PCa on AS have moderate rates of disease progression requiring treatment at 10 yr. Metastasis and PCSM rates were low, but confidence intervals are wide and require external validation. Positive mpMRI and increased PSAD were associated with disease progression and can help tailor AS intensity.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Shee K, Song JJ, Cowan JE, et al. The Nature of Progression on Active Surveillance for Favorable-risk Gleason Grade Group 2 Prostate Cancer. Eur Urol Oncol. 2026. PMID: 42918709. doi:10.1016/j.euo.2026.10.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。